Table 2.

Pharmacokinetic parameters of SB5794 and SB2617 in BALB/c mice (single-dose TK study)^a,b

PK parameters	SB5794 (p.o.)				SB2617 (p.o.)
	100 mg/kg	300 mg/kg	1000 mg/kg		100 mg/kg	300 mg/kg
Terminal t1/2 (h)	-	-	-		29.70	31.5
Tmax (h)c	11.3	17.3	26.0		7.3	14.7
Cmax (ng/mL)	12600	23733	51500		1502	2659
AUC0-24 (ng·h/mL)	261982	509222	1100298		32107	57542
AUC0-last (ng·h/mL)	325175	641778	1396410		-	-
AUC vs SB2617 10 mg/kg	15.0	29.2	63.2		1.8	3.4

ᵃMice (n=3 per group) received SB5794 (100, 300, or 1000 mg/kg) or SB2617 (100 or 300 mg/kg) orally. ᵇSB5794 demonstrated significantly improved C_max and AUC compared with SB2617. ᶜT_max is given as median.